FDA approves Isembyld for spinal muscular atrophy in patients two years and older

Isembyld, a treatment for spinal muscular atrophy (SMA), has received FDA approval for patients aged two years and older. The drug targets the neuromuscular disease that affects motor function. Approval opens the door to expanded use in the pediatric and adult SMA population. Market reaction will depend on the drug's label, pricing, and competition from existing therapies like Biogen's Spinraza and Novartis' Zolgensma.